Showing 911-920 of 9108 results for "".
DermWireTV: Atopic Dermatitis Pipeline Watch, a Potential New Skin Cancer Treatment; Demystifying Itch, and the Premiere of PA Perspectives
https://practicaldermatology.com/topics/practice-management/dermwiretv-atopic-dermatitis-pipeline-watch-a-potential-new-skin-cancer-treatment-demystifying-itch-and-the-premiere-of-pa-perspectives/20228/Escient Pharmaceuticals, Rapt Therapeutics, and Connect Biopharma each report positive results from early clinical studies in AD. Finnish researchers discover a potential treatment for cutaneous squamous cell carcinoma in an existing chemotherapy drug. Research out of Harvard Medical School links ecWeighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clSkin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-skin-cancer-perceptions-cimzia-for-psoriasis-eczema-and-cv-risk/18301/A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti TConnective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.Addressing Skin Changes During Menopause: An Update
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/addressing-skin-changes-during-menopause-an-update/20220/New York City-based dermatologist Ellen Gendler, MD, shares pearls from her recent talk at the 2023 annual meeting of the Menopause Society including the current thinking on how to address the effects of diminished estrogen on skin.Commitment to Clinical Evidence in Regenerative Aesthetics
https://practicaldermatology.com/videos/c-suite-chats/commitment-to-clinical-evidence-in-regenerative-aesthetics/54693/Laura Ellis, MD, CEO and Co-Founder of LevEllis, Inc., discusses the current state of aesthetic regenerative medicine and the importance of clinical evidence as the field continues to advance.Considerations for the Use of Biologics in Children with Atopic Dermatitis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/derm-hub/37152/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains the most important factors to understand when prescribing biologics for pediatric atopicImproving Care Options for CTCL
https://practicaldermatology.com/videos/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.A Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituFirst Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/videos/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testing